Relugolix for treating hormone-sensitive prostate cancer (TA995)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 August 2024
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (TA994)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2024
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2023
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 May 2023
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 August 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 July 2021
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2020
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2019
Padeliporfin for untreated localised prostate cancer (TA546)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 November 2018
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 August 2016Published: 25 May 2016
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 April 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2006
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 January 2025
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC